Page 3 - தேஜீந்தர் கன்னி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Khiron Partners with Colombia Cancer League to Deliver 3,000 Medical Cannabis Patient Consultations
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Khiron Partners with Colombia Cancer League to Deliver 3,000 Medical Cannabis Patient Consultations
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Khiron to Host First Quarter 2021 Conference Call on May 28, 2021
News provided by
Share this article
Share this article
TORONTO, May 19, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, today announces that it will host a conference call on Friday, May 28, 2021 at 10:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2021. The Company will provide its financial results in a press release prior to the conference call.
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Company s First Quarter 2021 Conference Call, followed by a Q&A session.
Psychopharmacology.
The project, poised to provide patients access to affordable medical cannabis treatment, was launched in 2019 at the Royal College of Psychiatrists in London.
The UK s national medical cannabis registry is monitored by an independent scientific body, Drug Science.
Vertically integrated CPG cannabis company
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) was the first supplier of EU-GMP high-THC dried cannabis flower to Project Twenty 21 s findings. Khiron, which has core operations in Latin America, is a founding member of Project Twenty 21.
Project Twenty 21 s Findings
The findings suggest that patients living with chronic pain, multiple sclerosis, Tourette s syndrome, epilepsy and post-traumatic stress disorder could significantly improve their quality of life by using legally prescribed cannabis.
(1)
Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study
The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette s Syndrome and PTSD
Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to avoid dependency associated with other medicines commonly prescribed for these debilitating conditions
TORONTO, May 11, 2021 /PRNewswire/ Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, applauds the publication today in the accredited scientific journal Psychopharmacology of the first findings arising from Project Twenty 21, UK s first and largest national medical cannabis registry that was launched on November
vimarsana © 2020. All Rights Reserved.